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ABSTRACT We conducted a large global survey, Still Fighting for Breath, in patients with severe
persistent asthma, 10 years after the Fighting for Breath survey to assess the impact of disease on patients’
lives and to determine if control and management have changed in recent years.
Data were collected from 1333 adults (aged >18 years) and caregivers of children (aged 6–17 years) with
severe persistent asthma from nine countries through an online survey conducted in 2016 by GfK.
A decade after the first survey, our results showed that the impact of severe asthma has not changed
significantly and a high proportion of patients with severe asthma remain inadequately controlled. A large
discrepancy was observed between the proportion of patients who perceived their asthma to be well
controlled (42%) and the proportion of patients who reported to be well controlled as per the Global
Initiative for Asthma (GINA) assessment (6%). Although most patients perceived their asthma to be
controlled, many experienced frequent symptoms that affected their daily lives.
Thus, there is a need for improved management (support and strategies) of patients with severe
persistent asthma and improved coordination of efforts that would enable these patients to achieve better
disease control.
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Introduction
Patients with severe asthma experience poorer quality of life and are at an increased risk of exacerbations,
hospitalisations and death due to poor disease control [1–3]. Since 2006, achieving good asthma control in
these patients has been the cornerstone of the Global Initiative for Asthma (GINA) management strategy
aiming to reduce the impact of the disease on patients’ daily activities [4, 5]. However, several real-life
surveys have shown that asthma control still remains an unmet goal [6].
Previous surveys have reported the major impact of asthma on patients’ lives due to the lack of control
[7–9]. Many patients with severe persistent asthma were unable to lead regular lives due to a low level of
asthma control [10–12]. Notably, approximately half of patients who were clinically adjudged to have
severe persistent symptoms considered their asthma to be well controlled [10, 13].
Fighting for Breath was a large-scale survey, conducted by the European Federation of Allergy and Airways
Diseases Patients’ Associations (EFA) between 2004 and 2005, to understand the impact of severe asthma
on patients’ lives [14, 15]. The results indicated that the majority of patients with severe asthma
experienced substantial limitations in their life as a consequence of the uncontrolled disease. However,
substantial time has passed since such a large-scale survey has been performed, specifically in patients with
severe asthma [10, 13–15].
We conducted a large, global, real-life survey, Still Fighting for Breath, aimed to assess the current impact
of severe persistent asthma on patients’ daily lives and activities. This survey provides a well-timed
evaluation to determine whether disease control and management of patients with severe persistent asthma
have changed in recent years.
Methods
Participants
Adult patients aged >18 years and caregivers of patients aged 6–17 years (paediatric and adolescent
patients) with severe persistent asthma were included in this survey. Participants were enrolled from nine
TABLE 1 Distribution, demographics and disease profile of survey participants by country
Adult patients Adolescent patients# Paediatric patients# Total
Country
UK 190 18 11 219
Germany 170 14 10 194
France 170 15 15 200
Italy 116 5 5 126
Brazil 150 10 20 180
Canada 150 3 6 159
Spain 115 4 16 135
Japan 90 0 0 90
Portugal 30 0 0 30
Total 1181 69 83 1333
Male/female % 44/56 39/61 27/73
Mean±SD age years
Male 42.0±13.3 14.0±1.5 8.0±1.5
Female 44.0±13.6 14.0±1.8 8.0±1.8
Smoking %
Current smokers 20.0
Ex-smokers 24.0
Never smoked 54.0
E-cigarette smokers 2.0
Disease duration, median years 16.0 7.0 3.0
Proportion of patients diagnosed with allergic asthma % 52.0 55.0 67.0 53.0
Proportion of patients diagnosed with nonallergic asthma % 48.0 45.0 33.0 47.0
Proportion of patients diagnosed by %
Respiratory physician 42.0
General practitioner 30.0
Allergist 21.0
Paediatrician 6.0
Other 1.0
Data are presented as n, unless otherwise stated. #: data for adolescent and paediatric patients were captured through their caregivers.
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countries (UK, Germany, France, Italy, Spain, Brazil, Canada, Japan and Portugal). Patients and caregivers
of paediatric and adolescent patients, mainly identified via databases (consumer panels), were invited to
complete the screening questionnaire and were included in this survey only if they met the criteria for
severe asthma.
Survey description
Data were collected using a 20-minute online survey, conducted by GfK on behalf of Novartis, between
July 12, 2016 and October 31, 2016. Patients/caregivers completed the questionnaire on asthma control,
daily/physical activity, exacerbations, psychological aspects and treatment.
TABLE 2 Impact of asthma on psychological wellbeing.
Adult Adolescent# Paediatric# Total
Prominent words associated with asthma %
Breathlessness/suffocation 17.0 3.0 2.0 16.0
Bad/uncomfortable 6.0 7.0 5.0 6.0
Stress/anxiety 5.0 12.0 4.0 5.0
Fatigue/tiredness 4.0 0 4.0 4.0
Respiration 4.0 6.0 1.0 4.0
Pain/suffering 3.0 7.0 4.0 4.0
Limited 3.0 6.0 1.0 3.0
Symptoms during exacerbations %
Cough 59.0 62.0 69.0 60.0
Daytime wheezing 57.0 62.0 52.0 57.0
Night-time wheezing 55.0 55.0 57.0 55.0
Persistent shortness of breath 57.0 64.0 43.0 57.0
Breathlessness while lying down 55.0 51.0 43.0 54.0
Fatigue 52.0 55.0 40.0 52.0
Associated psychological condition %
Anxiety 40.1 42.0 39.0 18.0
Depression 28.2 30.0 13.0 10.0
Other psychological condition 3.0 0 0 2.0
None of the above 47.0 54.0 78.0 49.0
Overall psychological impact %
Feel limited because of asthma 47.0 42.0 25.0 45.0
Feel dependent on the medication 41.0 25.0 23.0 39.0
Feel scared because of potential attack 34.0 33.0 27.0 33.0
Able to deal with asthma 30.0 36.0 34.0 31.0
#: data for adolescent and paediatric patients were captured through their caregivers.
TABLE 3 Distribution of anxiety and depression by country
Country Prevalence in severe asthma
patients# %
Prevalence in general population¶
%
Anxiety Depression Anxiety Depression
Global 40.1 28.2 3.6 4.4
UK 39.7 35.6 4.2 4.5
Germany 36.1 40.7 5.8 5.2
France 41.5 20.5 6.2 4.8
Italy 51.6 29.4 5.0 5.1
Brazil 46.7 27.2 9.3 5.8
Canada 38.4 28.9 4.9 4.7
Spain 29.6 21.5 4.1 5.2
Japan 40.0 13.3 3.1 4.2
Portugal 30.0 16.7 4.9 5.7
#: results from the Still Fighting for Breath survey; ¶: results from World Health Organization report [34].
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Definition and assessment of severity
Experiencing severe symptoms throughout the previous year was considered as severe persistent asthma.
Severity of disease was self-reported by patients based on the question: “Thinking about the severity of
your/your child’s asthma, what did your doctor tell you the last time you talked about severity?” This
answer was further validated using the GINA questionnaire.
Assessment of asthma control as per GINA guidelines
Asthma control assessment according to GINA is based on four questions: In the past 4 weeks, has the
patient had (yes/no): 1) …daytime symptoms more than twice a week?; 2) …any night waking due to
TABLE 4 Impact of asthma on daily activities in patients with severe persistent asthma
Adult Adolescent# Paediatric# Total
Impact on patients’ lives %
Disruption of activities of daily living 89.0 84.0 67.0 88.0
Disruption of physical activities 84.0 90.0 89.0 84.0
Disruption of sleep 97.0
Negative impact on self-esteem 53.0 45.0 32.0 51.0
Negative impact on professional life 58.0 36.0¶ 55.0
Wellbeing assessment %
Felt cheerful and in good spirits 4.0 3.0¶ 4.0
Felt calm and relaxed 5.0 3.0¶ 5.0
Felt active and vigorous 11.0 2.0¶ 10.0
Woke up feeling fresh and relaxed 15.0 9.0¶ 14.0
Daily life has been filled with things that interest me 6.0 5.0¶ 6.0
#: data for adolescent and paediatric patients were captured through their caregivers. ¶: Data are reported
for the caregivers of the adolescent and paediatric patients.
a)
Adolescent patients
Paediatric patients
Adult patients
Total
Well controlled
Patients %
0 10 20 30 40 50 60 70 80 90 100
b)
Adolescent patients
Paediatric patients
Adult patients
Total
Patients %
0 10 20 30 40 50 60 70 80 90 100
42 50 7
41 51 8
45 51 4
63 35 2
44 506
48 3120
58 384
43 525
Partly controlled Uncontrolled
FIGURE 1 Level of control a) as perceived by patients, and b) as per the Global Initiative for Asthma control
questionnaire. Rounding differences may be observed for these data.
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asthma?; 3) …the need for reliever medication more than twice a week?; and 4) …any activity limitations
due to asthma? Patients experiencing none of the above symptoms were categorised as well controlled;
patients experiencing one or two of the symptoms were considered as partly controlled and those
experiencing three or four of the symptoms were considered to be uncontrolled patients.
Results
Participants
A total of 1333 patients were surveyed, 1181 of whom were adults and 152 were caregivers of paediatric
and adolescent patients. Overall, 53% of the total survey population was diagnosed with allergic asthma,
reported based on patient knowledge. The country-wise patient distribution, demographics and disease
profile are shown in table 1.
Clinical and psychological impact
In the previous year, 73% of the total population experienced at least one exacerbation, of these, 34%
experienced more than two exacerbations that required emergency treatment (intervention by a healthcare
professional (HCP), emergency room visit, ambulance use, or physician at home). Overall, 51% of patients
a)
Level of control as per GINA 
control questionnaire
Level of control as perceived
by patients
Patients %
0 10 20 30 40 50 60 70 80 90 100
35 613
55 936
b)
Level of control as per GINA 
control questionnaire
Level of control as perceived
by patients
Patients %
0 10 20 30 40 50 60 70 80 90 100
47 646
49 438
Well controlled Partly controlled Uncontrolled
FIGURE 2 Level of control in a) high oral corticosteroid users and b) low oral corticosteroid users. Rounding
differences may be observed for these data. GINA: Global Initiative for Asthma.
TABLE 5 Comparison of Fighting for Breath and Still Fighting for Breath survey results
Parameter Fighting for Breath survey Still Fighting for Breath survey
Year of study 2005 2016
Total population n 1300 1333
Disturbed sleep % 42.0 (about once a week) 97.0
24.0 (more than once week)
Wheezing % 42.0 (about once a week) 57.0
24.0 (more than once week)
Missed going out with friends % 38.0 52.0
Missed out job opportunities % 21.0 24.0 (I worry that I will lose my job)
Missed holidays % 28.0 39.0
Physical activities % 84.0 69.0
Missed joining in at school or at college % 14.0 20.0
Having pets % 49.0 40.0
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who had an exacerbation that required emergency treatment clinically recovered within 24 h, although
13% required ⩾1 week to recover. However, emotional/psychological recovery took longer, with 39% of
patients recovering within 24 h, while 21% needed ⩾1 week to recover. Of the total population, 50%
reported having been clinically diagnosed with a psychological condition by an HCP. A detailed
description of the impact of asthma on psychological wellbeing and daily activities is given in tables 2–4.
Impact on daily and professional lives
The majority of patients reported disruption of “physical activities” (84%), “activities of daily living” (88%)
and “sleep” (97%). Of the total population, 58% of adult patients and 36% of caregivers perceived asthma
to be negatively affecting their professional working lives, with the main factors being “not able to
concentrate”, “taking time off due to asthma”, and “not being able to be fully productive”.
Asthma control
In the total population, a large discrepancy was observed between the proportion of patients who
perceived their asthma to be well controlled (42%) and the proportion of patients who were reported as
well controlled as per GINA assessment (6%); similar discrepancies were also observed in the adult,
adolescent and paediatric subpopulations (figure 1).
Most patients (91%) who used oral corticosteroids (OCSs) for ⩾14 days (high OCS users) perceived their
disease to be either partly controlled or well controlled; however, only 38% of these patients were partially
or well controlled as per GINA assessment. There was a strong disconnect between the patient’s
perception and GINA assessment of disease control in both low and high OCS users (figure 2).
Treatment
Of the total population, 58% of patients received short-acting rescue medication on top of the
maintenance treatment. The mean duration of OCS use was reported to be 20 days in the last 6 months,
while 63% of patients surveyed used OCSs on fewer than 14 days in the last 6 months (low OCS users).
Discussion
The observed impact of severe asthma on patients included in our survey was similar to that reported in
the Fighting for Breath survey conducted in 2005 [14, 15]. Comparison of key parameters between the
Medical
specialistCaregivers
Patient
Favour nurse
intervention to
improve inhaler
technique
Improved
adherence
Check/treat
comorbidities
Favour patient’s
referral to specialised 
centres for severe 
asthma
Favour patient’s
referral to
asthma specialist
Improved
asthma
control
Improved
asthma
control
Check/avoid
exposure to
triggers
Exclude
alternative
diagnosis
Perception 
of control
Smoking
InactivityObesity
Lack of
education
FIGURE 3 Holistic approach for severe asthma management.
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Fighting for Breath and Still Fighting for Breath surveys is presented in table 5. It should be noted that a
comparison in terms of the extent of asthma control between the two surveys may not be possible as
assessment of control was not included in the GINA guidelines when the previous survey was performed.
However, our results suggest that most patients with severe asthma still experience a lack of control and
poor quality of life. Our survey also shows that there is a significant disconnect between guideline-defined
asthma control and patient-perceived asthma control in patients with severe asthma. This was reflected in
the large discrepancy observed between the proportion of patients who perceived their asthma to be well
controlled (42%) and the proportion of patients who were reported as well controlled as per GINA
assessment (6%). As per our survey, only 58% of patients reported that they were taking short-acting
β-agonists (SABAs) on top of the maintenance therapy. However, we would expect that all patients used
SABA as a reliever medication. We believe that the misperception of asthma control may have led to the
nonusage of SABAs by all patients, considering that from the 42% that believed their asthma was well
controlled, only 6% were well controlled as per the GINA assessment. These 42% were not using SABAs as
reliever medication. However, due to the design of the survey it cannot be determined if these patients
were also not well educated, were nonadherent or were using additional long-acting muscarinic antagonists
(LAMAs) and/or monoclonal antibodies instead of SABAs. There are reports about asthmatics using
biologics showing a reduction in SABA use [16].
Several factors may be responsible for this lack of asthma control, including inadequate or non-personalised
disease-management support for individuals, inappropriate pharmacological treatment, nonadherence or
inadequate adherence to medication, poor inhaler technique and poor adherence to the overall asthma
management plan, and lack of referral to a specialist or poor diagnosis/asthma management by the HCP
[4, 17, 18].
In the Fighting for Breath survey, patients were asked to indicate the possible reasons for their poor
quality of life. The three major reasons reported were exposure to passive smoking, lack of treatment by a
specialist and absence of new treatments [14, 15]. Consequently, in the past decade, various steps have
been taken to improve the quality of life of asthma patients. These include: implementation of laws
banning smoking in public spaces [19, 20], introducing new treatments such as monoclonal
antibody-based therapies [21], and guideline-recommended new indication of LAMAs [22] for the
effective treatment of patients with asthma. After a decade, our results show that patients with asthma still
have a poor quality of life and experience symptoms that affect their daily lives. Though it should be noted
that there is no information whether patients included in our survey were eligible for (or on), monoclonal
antibody-based therapies.
Proper perception of control is associated with improved asthma-related health status as well as decreased
prospective risk for severe exacerbations [23]. Patients’ perception of asthma control can influence both
adherence to treatment and care by physicians; a better understanding of disease and disease control is
therefore important in order to achieve optimal treatment outcomes and improve asthma management [24,
25]. Poor perception of symptoms may lead to incorrect or under-treatment resulting in increased
morbidity and mortality from asthma [26]. Various factors have been associated with this poor perception
of control. These include smoking [27, 28], psychological factors such as anxiety and depression (common
in people with severe asthma) [29, 30], obesity, physical inactivity [31], and low educational status. There
have also been efforts to further educate HCPs to take informed decisions on when to refer patients with
severe asthma to specialist centres and to educate patients on ways to understand and recognise their
disease condition and symptom control [32, 33]. However, the results of our survey show that patients with
severe asthma still have a poor perception of symptom control leading to poor quality of life, but if we are
to empower patients this cannot be placed as the fault of the individual. Although a majority of patients
perceived their asthma to be controlled, many still experienced frequent symptoms that affected their daily
lives, and 73% of patients reported exacerbations that required HCP intervention. Furthermore, proportion
of population suffering from psychological condition in this survey (anxiety, 40.1%; depression, 28%) was
substantially higher than observed in general population (anxiety, 3.6%; depression, 4.4%) [34] (table 3).
This suggests that a high proportion of patients “had a poor perception of their asthma” and did not
recognise the extent of their symptoms due to asthma, thus tending to overestimate their disease control.
Hence, we propose to include perception of control in patients with asthma as a crucial component of
disease assessment and management in order to facilitate improving control in these patients.
The current survey results also highlight that depression and anxiety due to asthma maybe important
conditions that are either not revealed or are underestimated. Namely, half of the population surveyed here
reported being diagnosed with a psychological condition, with the majority of the patients suffering from
anxiety and depression, which is similar to the findings reported previously [35, 36].
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There are some limitations of this survey: data presented herein were obtained via an online survey; hence,
the data were self-reported by patients or their caregivers and were not clinically verified and thus,
inaccurate responses due to poor recall cannot be excluded. Moreover, it is difficult to precisely predict the
actual factors behind participant responses. Data for minor patients were reported by their caregivers;
these responses may not be reflective of the actual situation, especially the smoking status among these
patients. The definition of severe asthma was based on patient-reported symptom history in the past year
and was not as definitive as provided by the guidelines.
Overall, our survey highlights that a substantial gap remains between guideline-defined and patient-
perceived asthma control in patients with severe asthma. Over a decade after the Fighting for Breath survey
was conducted, little seems to have changed in terms of the quality of life of patients with severe asthma.
Severe asthma patients still live with uncontrolled asthma, experience exacerbations, suffer from
psychological symptoms and have an unacceptable level of quality of life. Moreover, patients’ perception of
“asthma control”, and their expectations of “good asthma control” appear alarmingly low. This is despite a
decade of increased research and resource provision in severe asthma, multiple changes to guidelines and
new advancements in pharmacological intervention. Severe asthma patients are Still Fighting for Breath and
we advocate a thorough reconsideration of our approach to the management of severe asthma (figure 3). If
no action is taken, it is unlikely that the next 10 years will see any substantial change in the quality of lives
of severe asthma patients in all age groups. Our proposals are: to develop tools to assess asthma symptom
perception and to subsequently include such a measure in the routine assessment of patients with asthma;
and to reinforce the education of asthma patients through HCPs and patient organisations.
Conclusions
This large-scale global survey showed that severe persistent asthma has a major impact on patients,
affecting their daily and professional activities, and having a negative impact on their psychological
condition. Most patients with severe asthma remain inadequately controlled. In addition, there is a strong
disconnect between guideline-defined and patient-perceived asthma control. Thus, there is a need for
improved management (support and strategies) of patients with severe persistent asthma and better
coordination of efforts including those aimed at enhancing asthma education, assessing perception of
control, patient–physician interaction, guideline implementation, treatment adherence and involvement of
patient organisations. Implementation of these measures would go some way to enabling these patients to
achieve better disease control.
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